Prot# GS-US-236-0115: A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emt

Project: Research project

Project Details

StatusFinished
Effective start/end date1/16/121/16/15

Funding

  • Gilead Sciences, Inc (GS-US-236-0115)